AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 268.9 USD | +2.35% |
|
+0.62% | -6.63% |
| 11:11pm | Wall Street: tech and SOXX in free fall this week | CF |
| Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Financials (USD)
| Sales 2024 * | 32.97B | Sales 2025 * | 34.15B | Capitalization | 141B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.1B | Net income 2025 * | 7.56B | EV / Sales 2024 * | 5.68 x |
| Net Debt 2024 * | 46.47B | Net Debt 2025 * | 40.28B | EV / Sales 2025 * | 5.31 x |
| P/E ratio 2024 * |
22.9
x | P/E ratio 2025 * |
17.7
x | Employees | 26,700 |
| Yield 2024 * |
3.53% | Yield 2025 * |
3.82% | Free-Float | 99.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | +1.04% | ||
| 1 week | +0.62% | ||
| Current month | -5.41% | ||
| 1 month | -1.03% | ||
| 3 months | -12.63% | ||
| 6 months | -4.16% | ||
| Current year | -6.63% |
1 week
260.68
270.93
1 month
260.68288.57
Current year
260.68329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.30329.72
10 years
108.20329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | Dec. 17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 120 M€ | +9.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 268.9 | +2.35% | 3 379 979 |
| 24-04-18 | 262.8 | -0.50% | 2,082,791 |
| 24-04-17 | 264.1 | -0.59% | 2,175,120 |
| 24-04-16 | 265.6 | +0.05% | 2,017,573 |
| 24-04-15 | 265.5 | -0.66% | 1,740,174 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
262.8
USD
Average target price
300.3
USD
Spread / Average Target
+14.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.63% | 141B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -3.20% | 113B |
- Stock Market
- Equities
- AMGN Stock
